Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus methotrexate in recurrent or metastatic head and neck squamous cell carcinoma
2013-002886-20Phase 2Completed
- Sponsor
- Radboud University Medical Center
- Start
- Sep 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of cetuximab and methotrexate in head and neck squamous cell carcinoma (HNSCC), sponsored by Radboud University Medical Center. Started Sep 2013; status: completed.
02
Drugs
cetuximabmethotrexate
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2013-002886-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002886-20.